MMMolly O. Meeker

Molly O. Meeker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Molly O. Meeker has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Aidan Vanek

    Department of Otolaryngology–Head and Neck Surgery Nationwide Children's Hospital Columbus Ohio USA

    2 shared publications
  • Akhil Katragadda

    College of Medicine The Ohio State University Columbus Ohio USA

    2 shared publications
  • Alexandra Gach

    Department of Otolaryngology–Head and Neck Surgery Nationwide Children's Hospital Columbus Ohio USA

    2 shared publications
  • Apoorva Tewari Ramaswamy

    Department of Otolaryngology‐Head and Neck Surgery The Ohio State University Wexner Medical Center Columbus Ohio USA

    2 shared publications
  • Brad de Silva

    Department of Otolaryngology‐Head and Neck Surgery The Ohio State University Wexner Medical Center Columbus Ohio USA

    2 shared publications
  • Charles Elmaraghy

    Department of Otolaryngology–Head and Neck Surgery The Ohio State University Wexner Medical Center Columbus Ohio USA

    2 shared publications

Latest Publications

  • Open Access

    Utilization of the Child Opportunity Index to Evaluate Timing of Tympanostomy Tube Placement

    by Molly O. Hunter, Jemma Maynard, Aidan Vanek, Alexandra Gach, Tatum Adamson, Kolby Quillin, Isaac Kistler, Charles Elmaraghy, Prasanth Pattisapu

    Objective: Socioeconomic factors including social determinants of health (SDOH) have been implicated in tympanostomy tube (TT) placement and otorrhea. The objective of this study was to determine whether SDOH play a role in delays from presentation to TT placement. Study Design: Retrospective cohort study. Setting: Tertiary Care Center. Methods: A retrospective chart review of patients 0 to 4 years old with first‐time TT placement between January 1, 2023, and July 1, 2023, measured SDOH using nationally averaged Child Opportunity Index (COI) 3.0 data at the census‐tract level. COI quintiles were dichotomized into low SDOH (very low and low COI) and not low SDOH (moderate, high, and very high COI). Results: A total of 962 patients met the inclusion criteria. Patients with low SDOH were more likely to be non‐Hispanic black than patients without low SDOH (18% vs 4.5%) and more likely to have Medicaid insurance (62% vs 32%). Children with low SDOH traveled further for surgery than children without low SDOH (40 miles vs 20 miles). Time from surgery order to surgery was longer in children with low SDOH than those without even when adjusted for race/ethnicity, insurance, and clinical features. Time from last ear infection to initial presentation was also longer for children with low SDOH than for others in our unadjusted analysis; however, those with low SDOH had a shorter time in our adjusted analysis. Conclusion: Children with low SDOH traveled longer distances for care and experienced significant delays to surgery. These findings support future research on transportation access and other financial interventions for these at‐risk children.

  • Open Access

    CMS Exclusion of Global Period Visits From E/M Payment Reform: Estimated Payment Loss for Pediatric Otolaryngologists

    by Ashley L. Miller, Vinay K. Rathi, Molly O. Meeker, Lauren E. Miller, Jason Pedicini, Charles A. Elmaraghy

    In an effort enhance reimbursement for cognitive specialties, the Centers for Medicare and Medicaid Services (CMS) increased the payment for outpatient and inpatient E&M services in 2021 and 2023, respectively. Notably, visits during the postoperative global period were excluded from this increase. It is well‐established that pediatric subspecialties, including pediatric otolaryngology, are less well‐compensated than their adult counterparts. In this study, we estimated the potential annual revenue increase per academic pediatric otolaryngologist had CMS included global period visits in its revaluation.

  • Impact of unmet social needs on timing of tympanostomy tube placement

    by Molly O. Meeker, Jemma Maynard, Aidan Vanek, Alexandra Gach, Tatum Adamson, Kolby Quillin, Isaac Kistler, Prasanth Pattisapu, Charles Elmaraghy


  • Open Access

    Comparison of Esophageal Dysmotility Diagnostic Studies in Head and Neck Cancer Survivors With Dysphagia

    by Akhil Katragadda, Molly O. Meeker, Mohammad Bilal Alsavaf, Jack Birkenbeuel, Zachary Wykoff, Songzhu Zhao, Apoorva Ramaswamy

    Objective: This study aims to characterize the relationship of esophageal dysmotility on modified barium swallow (MBS) and esophagram studies with high‐resolution manometry (HRM), the gold standard of esophageal dysmotility diagnosis, in head and neck cancer (HNC) survivors with dysphagia.Study Design: Retrospective diagnostic accuracy study.Setting: Specialty dysphagia clinic at a tertiary care center.Methods: A retrospective analysis of 30 patients treated for dysphagia between 2020 and 2023 was conducted. Inclusion criteria required HNC survivors aged 18 years or older who were diagnosed with dysphagia, treated in a HNC dysphagia clinic, and completed at least one HRM study. Data were collected on patient demographics, cancer history, MBS, esophagram, and HRM studies. MBS and esophagram results were reviewed for evidence of esophageal dysmotility. HRM studies were assessed with the Chicago Classification Version 4.0. Data were summarized and analyzed using t test for continuous variables and a chi‐square test for categorical variables. McNemar's test and diagnostic odds ratios were calculated to compare diagnostic test results.Results: Of the 30 patients reviewed, 20 (67%) showed dysmotility on HRM, 15 (50.0%) completed MBS only, 2 (6.7%) completed esophagram only, and 13 (43.3%) completed both MBS and esophagram. MBS and esophagram accurately identified dysmotility in 66.7% and 76.9% of patients with confirmed dysmotility on HRM, respectively.Conclusion: Esophageal dysmotility is an understudied comorbidity of dysphagia in the HNC survivor population. Our study suggests that MBS and esophagram have limited predictive value in the assessment of dysmotility in HNC survivors with dysphagia. Thus, future studies should aim to better understand the relationship between other aspects of post‐HNC dysphagia and esophageal dysmotility.


  • Dysplasia and Carcinoma in Recurrent Respiratory Papillomatosis Patients Older Than 45 Years

    by Molly O. Meeker, Ryan Ivancic, Brad de Silva, Laura A. Matrka

    Objectives: Variable evidence on risk factors for dysplasia and malignant transformation in RRP exists. Dysplasia has been reported in 10%–55% of adult recurrent respiratory papillomatosis (RRP) patients, but existing literature may misrepresent typical adult RRP age ranges. We aim to evaluate risk factors for the development of dysplasia and malignancy in RRP patients > 45 years old.Methods: We conducted a retrospective chart review of adult patients diagnosed with RRP > 45 years of age from 2008 to 2022. A two‐tailed t‐test was performed for continuous variables, and Chi‐squared analysis and Fisher's exact test were used for categorical variables.Results: There were 49 total patients with a mean age of 58.7 (45–80) years; 28 (57%) had some degree of dysplasia; 21 (43%) had no dysplasia. Of those with dysplasia, 9 (32%) had high‐grade, and 19 (68%) had low‐grade. Seven (14%) patients developed laryngeal squamous cell carcinoma; high‐grade (5/7) was more likely than low‐grade (2/7) dysplasia to progress to carcinoma (p = 0.012). A history of smoking and pack‐years was associated with dysplasia (p = 0.044 and p = 0.018 respectively) but not malignancy. Laryngopharyngeal reflux, alcohol use, diabetes, or immunosuppression were not associated with dysplasia or malignancy. Of note, no patient who developed malignancy had received Gardasil vaccination (p = 0.08).Conclusions: Our study of RRP patients > 45 years old shows a higher incidence of dysplasia than current literature reports for adult patients > 18 years. Smoking history was correlated with dysplasia but not malignancy. All patients who developed malignancy demonstrated previous dysplasia, and malignant transformation was significantly associated with high‐grade dysplasia.Level of Evidence: 3.


  • Update on Gardasil Vaccination in Recurrent Respiratory Papillomatosis Patients Aged 45 or Older

    by Molly O. Meeker, Ryan Ivancic, Brad de Silva, Laura A. Matrka

    Objective: Gardasil vaccination has been effective as primary prevention and adjuvant therapy for recurrent respiratory papillomatosis (RRP). We present an update to our previous research reporting a significant increase in the intersurgical interval (ISI) after adjuvant Gardasil vaccination. Our objectives were: (1) to assess the durability of Gardasil as an adjuvant in RRP with longer‐term follow‐up and an expanded cohort, and (2) to better control for the use of other non‐Gardasil adjuvant therapies.Methods: A retrospective chart review of adult patients > 45 years diagnosed with RRP from 2008 to 2022 was conducted. Patients were considered vaccinated if they received at least two Gardasil doses.Results: There were 51 total patients, 14 vaccinated and 37 unvaccinated. There was a significant increase in the ISI for the vaccinated group from 126 to 304 days (p = 0.0039), with 100.1 ± 47.3 months follow‐up. Our previous study, performed at 49.7 ± 30.3 months follow‐up, found an ISI of 494 days in the vaccinated group. Non‐Gardasil adjuvant use was greater in the vaccinated group, but we found no significant effect of non‐Gardasil adjuvant use on ISI in the unvaccinated group (p = 0.34).Conclusions: Adjuvant Gardasil use in RRP patients > 45 years significantly increases the ISI, which supports findings from our previous study. However, the magnitude of this effect may wane with time, with the ISI remaining significant but downtrending from 494 to 304 days. This data raise the question of whether booster Gardasil dosing warrants investigation.


  • Dysphagia in head and neck cancer patients with evidence of esophageal dysmotility on manometry

    by Bs Molly O. Meeker, Akhil Katragadda, Mohammad Bilal Alsavaf, Jack Birkenbeuel, Zachary Wykoff, Songzhu Zhao, Apoorva T. Ramaswamy


  • Evaluating utility of allergy testing in management of nasal obstruction following inferior turbinate reduction

    by Joseph Lee, Logan F. McColl, Molly O. Meeker, Tony Satroplus, Natalie Kelly, Kevin Liu, Amanda Onwuka, Tendy Chiang

  • Microvascular Regeneration and Perfusion of Partially Decellularized Tracheal Grafts

    by Ada C. Sher, Lumei Liu, Melwan Izem, Jazmin Calyeca, Molly O. Meeker, Tendy Chiang

    Objectives: A critical barrier to successful tracheal transplantation is poor vascularization. Despite its importance, little is known about microvascular regeneration in tissue‐engineered grafts. We have demonstrated that partially decellularized tracheal grafts (PDTG) support neotissue formation including new submucosal microvasculature (CD31+). However, the perfusion of this neovasculature is unknown. In this study, we used a mouse model of tracheal replacement to measure the microvascular regeneration and perfusion of PDTG.Methods: PDTG and syngeneic tracheal grafts (STG, surgical control) (n = 5 for each group) were orthotopically transplanted into C5BL/6 J mice. We quantified vascularity of STG and PDTG samples at 1 and 3 months with conventional histology (N = 3 ~ 10/group). At 1, 3, and 6 months, animals were injected with fluorescein isothiocyanate (FITC) tomato lectin into the left ventricle. After perfusion, tracheas were fixed, harvested, mounted, stained for CD31 expression, and imaged with resonant scanning confocal microscopy. Percent CD31+, FITC area was compared between groups and endpoints compared with native trachea. Microvascular intersections were quantified using Sholl analysis.Results: Functional microvasculature was seen in both groups. Although percent vascularization (CD31) in PDTG was restored by 3 months, microvascular pattern in PDTG displayed a unique morphology compared with control. Surgery alone appeared to globally change microvascular pattern and perfusion. PDTG demonstrated equivalent perfusion to surgical control by 6 months. Sholl analysis revealed a reduction of microvessel intersectionality that persisted in PDTG and was not seen in surgical or native controls.Conclusions: PDTG exhibited microvascular regeneration. Perfusion was present in PDTG, improved, and persisted over long‐term time points.Level of Evidence: NA Laryngoscope, 135:614–621, 2025